Docetaxel

Generic Name: Docetaxel

Brand Names: Taxotere, Docetaxel Accord, Docetaxel Kabi

Drug Type: Small Molecule

Chemical Formula: C_₄₃H_₅₃NO_₁₄

CAS Number: 114977-28-5

Unique Ingredient Identifier: 699121PHCA

Background: Docetaxel is a clinically well established anti-mitotic chemotherapy medication used for the treatment of different types of cancer, including breast, ovarian, and non-small cell lung cancer. Docetaxel is a complex diterpenoid molecule and a semisynthetic analogue of paclitaxel. Docetaxel reversibly binds to microtubulin with high affinity in a 1:1 stoichiom...

Indication: Docetaxel is indicated as a single agent for the treatment of locally advanced or metastatic breast cancer after chemotherapy failure; and with doxorubicin and cyclophosphamide as adjuvant treatment of operable node-positive BC. It is also indicated as a single agent for locally advanced or metastatic non-small cell lung cancer (NSCLC) after platinum therapy...

Associated Conditions: Esophageal Cancer, Ewing's Sarcoma, Locally Advanced Breast Cancer (LABC), Metastatic Bladder Cancer, Metastatic Breast Cancer, Metastatic Squamous Cell Carcinoma of the Head and Neck (HNSCC), Node Positive Breast Cancer, Ovarian Cancer Metastatic, Small Cell Lung Cancer (SCLC), Soft Tissue Sarcoma, Advanced untreated gastric adenocarcinoma, Locally advanced Squamous cell carcinoma of head and neck, Locally advanced untreated non small cell lung cancer, Metastatic untreated non small cell lung cancer, Refractory, locally advanced Non small cell lung cancer, Refractory, metastatic Non small cell lung cancer, Refractory, metastatic hormone-refractory Prostate cancer

Associated Therapies: -

Clinical Trials

Intravesical BCG vs GEMDOCE in NMIBC

Phase 3

Recruiting

Conditions: Non-muscle-invasive Bladder Cancer

Interventions: Drug: Bacillus Calmette Guerin
Drug: Gemcitabine
Drug: Docetaxel

First Posted Date: 2022-09-14

Last Posted Date: 2024-10-22

Lead Sponsor: ECOG-ACRIN Cancer Research Group

Target Recruit Count: 870

Registration Number: NCT05538663

Locations: 🇺🇸
CTCA at Western Regional Medical Center, Goodyear, Arizona, United States
🇺🇸
Cancer Center at Saint Joseph's, Phoenix, Arizona, United States
🇺🇸
Mission Hope Medical Oncology - Arroyo Grande, Arroyo Grande, California, United States

and more 225 locations

The Management of Metastatic Neck Nodes in N2/3 Hypopharyngeal Squamous Cell Carcinoma

Not Applicable

Recruiting

Conditions: Hypopharyngeal Carcinoma

Interventions: Radiation: Concomitant chemoradiotherapy
Drug: Docetaxel
Procedure: Surgery
Drug: Cisplatin
Drug: Capecitabine

First Posted Date: 2022-08-09

Last Posted Date: 2023-04-18

Lead Sponsor: Eye & ENT Hospital of Fudan University

Target Recruit Count: 111

Registration Number: NCT05494190

Locations: 🇨🇳
Harbin Medical University Cancer Hospital, Harbin, Heilongjiang, China
🇨🇳
Shandong Provincial ENT Hospital, Cheeloo College of Medicine, Shandong University, Jinan, Shandong, China
🇨🇳
Eye & ENT Hospital, Fudan University, Shanghai, Shanghai, China

The Efficacy and Safety of Docetaxel Combined With Platinum for Metastatic Hormone-sensitive Prostate Cancer

Phase 2

Recruiting

Conditions: Hormone Sensitive Metastatic Prostate Cancer
DNA Damage Repair Deficiency
Chemotherapy Effect
Chemotherapeutic Toxicity

Interventions: Drug: Docetaxel
Drug: Prednisolone Acetate
Drug: Platinum-based drugs

First Posted Date: 2022-07-18

Last Posted Date: 2022-10-24

Lead Sponsor: The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

Target Recruit Count: 50

Registration Number: NCT05461261

Locations: 🇨🇳
Department of Urology, Drum Tower Hospital, Medical School of Nanjing University, Institute of Urology, Nanjing University, Nanjing, Jiangsu, China

Study To Investigate the Efficacy and Safety of Sitravatinib in Combination With Tislelizumab in Participants With Esophageal Squamous Cell Carcinoma

Phase 2

Terminated

Conditions: Esophageal Squamous Cell Carcinoma

Interventions: Drug: Sitravatinib
Drug: Docetaxel
Drug: Tislelizumab
Drug: Irinotecan

First Posted Date: 2022-07-18

Last Posted Date: 2024-03-04

Lead Sponsor: BeiGene

Target Recruit Count: 96

Registration Number: NCT05461794

Locations: 🇨🇳
Sichuan Academy of Medical Sciences and Sichuan Provincial Peoples Hospital, Chengdu, Sichuan, China
🇨🇳
Union Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China
🇨🇳
The First Affiliated Hospital of Xinxiang Medical University, Xinxiang, Henan, China

and more 24 locations

A Phase III Study of Ceralasertib Plus Durvalumab Versus Docetaxel in Patients With Non Small Cell Lung Cancer (NSCLC) Whose Disease Progressed On or After Prior Anti PD (L)1 Therapy And Platinum Based Chemotherapy

Phase 3

Active, not recruiting

Conditions: Advanced or Metastatic Non-Small Cell Lung Cancer

Interventions: Drug: Ceralasertib
Drug: Docetaxel
Drug: Durvalumab

First Posted Date: 2022-07-11

Last Posted Date: 2024-12-19

Lead Sponsor: AstraZeneca

Target Recruit Count: 594

Registration Number: NCT05450692

Locations: 🇬🇧
Research Site, Wirral, United Kingdom

Pembrolizumab With Chemotherapy and MK-4830 for Treating Participants With Ovarian Cancer (MK-4830-002)

Phase 2

Completed

Conditions: High-grade Serous Ovarian Carcinoma
Ovarian Carcinoma

Interventions: Biological: Pembrolizumab
Drug: Paclitaxel
Drug: Carboplatin
Biological: Avastin
Biological: MK-4830
Drug: Docetaxel

First Posted Date: 2022-07-07

Last Posted Date: 2024-12-17

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 160

Registration Number: NCT05446870

Locations: 🇨🇳
Changhua Christian Hospital-Obstetrics and Gynecology ( Site 1203), Changhua County, Changhua, Taiwan
🇪🇸
Hospital Universitari Vall d'Hebron-Departamento de Oncologia- VHIO ( Site 1101), Barcelona, Spain
🇪🇸
Hospital Universitario 12 de Octubre-Medical Oncology ( Site 1104), Madrid, Madrid, Comunidad De, Spain

and more 42 locations